Abstract: The disclosed computer-implemented method for data management of multiple cloud services may include receiving, via a visibility application, a command for managing data hosted on a plurality of content sources. The commands from the visibility application may be modified and indirectly routed to the plurality of content sources. The method may include accessing, in response to the command, the plurality of content sources, and collecting and aggregating, from the plurality of content sources, metadata associated with the data. The method may also include analyzing the aggregated metadata. The method may further include providing, for presentation by the visibility application, results of the metadata analysis. Various other methods, systems, and computer-readable media are also disclosed.

Abstract: The present invention relates to a process which uses blue light to form bio-organic coated silver and gold nanoparticles for various applications. The present invention particularly relates to increasing the rates of reaction and widening the scope of tethering a range of biomolecules on the metal nanoparticles. The examples demonstrate that the biomolecules immobilized on the nanoparticles still retain many aspects of their structural elements which allow them to bind to their native binding partners and/or retain structural epitopes which allow them to be identified by antibodies specific to them, thus opening up scope of using such coated nanoparticles for functionalized and specific applications.

Abstract: The present invention relates to a process which uses blue light to form bio-organic coated silver and gold nanoparticles for various applications. The present invention particularly relates to increasing the rates of reaction and widening the scope of tethering a range of biomolecules on the metal nanoparticles. The examples demonstrate that the biomolecules immobilized on the nanoparticles still retain many aspects of their structural elements which allow them to bind to their native binding partners and/or retain structural epitopes which allow them to be identified by antibodies specific to them, thus opening up scope of using such coated nanoparticles for functionalized and specific applications.

Abstract: The present invention relates to the anti dengue activity of the cissampelos pareira extracts. Pharmaceutical compositions comprising extracts of cissampelos pareira and processes for the preparation of extracts of cissampelos pareira are also provided.

Abstract: The present invention relates to the anti dengue activity of the cissampelos pareira extracts. Pharmaceutical compositions comprising extracts of cissampelos pareira and processes for the preparation of extracts of cissampelos pareira are also provided.

Abstract: The invention provides peptides capable of binding with influenza hemagglutinin (HA) protein blocking pH-induced shape change or aggregation of the influenza hemagglutinin (HA) protein. The invention also provides a druggable site in influenza Hemagglutinin protein, said druggable site comprises peptide sequences comprising conserved residues.

Abstract: The present invention relates to an extract of Cissampelos pareira, its pharmaceutical compositions, and its therapeutic use in the prevention and treatment of dengue. It also relates to processes for the preparation of these extracts.

Abstract: Three important species of Aspergillus, A. fumigatus, A. flavus and A. niger are known to contribute to the pathogenicity of allergic and invasive diseases in humans. They are also known to be plant pathogens. Several important ESTs/genes of Aspergilli species are now identified and characterized. Efforts are still needed to explore 30% genes of Aspergillus species for their valuable products which need to be explored. Polyketide biosynthetic pathway in Aspergillus species produce important secondary metabolites like polyketide toxins such as Aflatoxins, drugs such as Lovastatins and several other important pharmaceutically important polyketide compounds etc. With the availability of Aspergillus genome sequences it is possible today to characterize the structure and function of important genes of Aspergillus species. Based on the gene sequence information on PKS enzymes in medically and agriculturally important Aspergillus species such as A. fumigatus, A. flavus and A.

Abstract: A platform to enable configuration, administration and management of augmented reality markers adapted to be scanned by an end user mobile device to enable AR experience. The platform enables control of marker provisioning by entities who decide what content should appear in mobile applications when their AR codes are scanned by end users. The platform generates unique AR markers. A marker has a first code region, and a second code region. The code regions are adapted to be scanned, preferably sequentially, and the first code region encodes a first identifier identifying an External marker ID in a pattern matching approach, and second code region that encodes a second identifier identifying an Internal marker ID in a encoding/decoding approach. In one embodiment, the first code region is generally circular and includes a central area, and the second code region is located within the central area of the first code region.

Abstract: A device may distribute client packets to multiple servers, transmit health check packets with a specific window size to the multiple servers, capture the client packets and the health check packets, and extract the health check packets from the captured packets. In addition, the device may capture packets, detect a connection problem, transmit a reset packet with a specific window size, and extract the reset packet from the captured packets.

Abstract: Three important species of Aspergillus, A. fumigatus, A. flavus and A. niger are known to contribute to the pathogenicity of allergic and invasive diseases in humans. They are also known to be plant pathogens. Several important ESTs/genes of Aspergilli species are now identified and characterized. Efforts are still needed to explore 30% genes of Aspergillus species for their valuable products which need to be explored. Polyketide biosynthetic pathway in Aspergillus species produce important secondary metabolites like polyketide toxins such as Aflatoxins, drugs such as Lovastatins and several other important pharmaceutically important polyketide compounds etc. With the availability of Aspergillus genome sequences it is possible today to characterize the structure and function of important genes of Aspergillus species. Based on the gene sequence information on PKS enzymes in medically and agriculturally important Aspergillus species such as A. fumigatus, A. flavus and A.

Abstract: The present invention relates to the anti dengue activity of the cissampelos pareira extracts. Pharmaceutical compositions comprising extracts of cissampelos pareira and processes for the preparation of extracts of cissampelos pareira are also provided.

Abstract: A device may distribute client packets to multiple servers, transmit health check packets with a specific window size to the multiple servers, capture the client packets and the health check packets, and extract the health check packets from the captured packets. In addition, the device may capture packets, detect a connection problem, transmit a reset packet with a specific window size, and extract the reset packet from the captured packets.

Abstract: The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.

Abstract: The invention relates to compounds having formula (I): Scaffold-[L-(Antigen)t]y (I) wherein Antigen represents at least a portion of a target antigen for modulating an immune response; wherein t is 0 or an integer of at least 1; wherein y is at least 1; wherein the number of Antigens on the Scaffold is at least 2; wherein L is a linking group or a covalent bond, wherein when L is a covalent bond, the covalent bond is a single bond attached to a sp or sp2 hybridized atom of the Scaffold and when L is a linking group, the linking group is attached to the Scaffold through a single bond attached to a sp or sp2 hybridized atom; whereby the Scaffold is sufficiently rigid to maintain the relative position of the single bonds attached to sp or sp2 hybridized atoms. Further described are compositions containing the compounds and methods of using them.

Abstract: The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.

Abstract: The present invention provides mutant Mycobacterium strains harboring a modified tyrosine phosphatase gene (mptpA or mptpB) wherein the mutant Mycobacterium strain is incapable of expressing the active tyrosine phosphatase. The invention provides a method for developing the said mutant strain from either Mycobacterium tuberculosis or Mycobacterium bovis. The mptpA or mptpB gene may be modified by replacing the internal sequences with an antibiotic resistance marker gene, which disrupts the expression of the active gene. The invention further provides a recombinant vector comprising the modified mptpA or mptpB which may be used to develop the mutant strains of mycobacteria. The invention provides a method to assess the role of tyrosine phosphatases MptpA and MptpB in the virulence and pathogenesis of Mycobacterium which can be used as potential targets for developing anti-tubercular drug.

Abstract: The invention relates to improved methods of producing and recovering B. anthracisprotective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.

Abstract: The present invention provides mutant Mycobacterium strains harboring a modified tyrosine phosphatase gene (mptpA or mptpB) wherein the mutant Mycobacterium strain is incapable of expressing the active tyrosine phosphatase. The invention provides a method for developing the said mutant strain from either Mycobacterium tuberculosis or Mycobacterium bovis. The mptpA or mptpB gene may be modified by replacing the internal sequences with an antibiotic resistance marker gene, which disrupts the expression of the active gene. The invention further provides a recombinant vector comprising the modified mptpA or mptpB which may be used to develop the mutant strains of mycobacteria. The invention provides a method to assess the role of tyrosine phosphatases MptpA and MptpB in the virulence and pathogenesis of Mycobacterium which can be used as potential targets for developing anti-tubercular drug.

Abstract: The present invention relates to a novel molecule useful for anthrax toxin inhibition in vivo and also provides a method for in vivo inhibition of anthrax toxin action using the new molecule.